AVNS earnings analysis
What we found in AVNS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Avanos Medical reported Q1 2026 revenue of $182.2 million, exceeding expectations and up 8.8% year-over-year, driven by a notable 22.7% growth in its Specialty Nutrition Systems segment. Diluted EPS of $0.22 also surpassed estimates, reflecting management's focus on operational restructuring amid ongoing tariff impacts.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Robust Revenue Growth
- Total revenue reached $182.2 million, up 8.8% from $167.5 million in Q1 2025.
- Strong EPS Performance
- Diluted EPS was reported at $0.22, exceeding the estimate of $0.16 and higher than the prior period's $0.14.
- Specialty Nutrition Systems Surge
- Specialty Nutrition Systems segment grew by 22.7%, contributing $124.0 million to total revenue.
- Cost Reduction Initiatives
- Restructuring efforts yield annualized savings expected between $15.0 million and $20.0 million.
- Reduced Interest Expense
- Interest expense decreased to $1.5 million from $2.1 million year-over-year, benefiting from lower debt levels.
- Operating Cash Flow Improvement
- Operating cash flow was negative but improved with cash usage down to $12.3 million in Q1 2026 from $25.7 million in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Negative Operating Margin
- Operating margin dropped to 4.9% in Q1 2026 from 6.0% in Q1 2025, indicating ongoing margin pressure.
- Cash Decrease
- Cash and cash equivalents declined by $24.2 million to $65.6 million, reflecting higher operational costs.
- Impact of Tariffs
- Increased tariffs contributed to rising costs in the Specialty Nutrition Systems segment, creating margin challenges.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.22
- Operating margin
- 4.9%
- Segment
- Specialty Nutrition Systems: $124M
- Segment
- Pain Management and Recovery: $56.3M
- Segment
- Corporate and Other: $1.9M
What they said about what is next.
Management expects to utilize operating cash flow for working capital needs; specific revenue guidance not provided.
The filing reads better than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AVNS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever